Biomedical subjects

Jeffrey Maki

Publications and source records attributed to Jeffrey Maki.

4 recordsLinked to original sources

PubMed2005

Effect of post-implant edema on prostate brachytherapy treatment margins.

PURPOSE: To determine if postimplant prostate brachytherapy treatment margins calculated on Day 0 differ substantially from those calculated on Day 30. METHODS: Thirty patients with 1997 American Joint Commission on Cancer clinical stage T1-T2 prostatic carcinoma underwent prostate brachytherapy with I-125 prescribed to 144 Gy. Treatment planning methods included using loose seeds in a modified peripheral loading pattern and treatment margins (TMs) of 5-8 mm. Postimplant plain radiographs, computed tomography scans, and magnetic resonance scans were obtained 1-4 hours after implantation (Day 0). A second set of imaging studies was obtained at 30 days after implantation (Day 30) and similarly analyzed. Treatment margins were measured as the radial distance in millimeters from the prostate edge to the 100% isodose line. The TMs were measured and tabulated at 90 degrees intervals around the prostate periphery at 0.6-cm intervals. Each direction was averaged to obtain the mean anterior, posterior, left, and right margins. RESULTS: The mean overall TM increased from 2.6 mm (+/-2.3) on Day 0 to 3.5 mm (+/-2.4) on Day 30. The mean anterior margin increased from 1.2 mm on Day 0 to 1.8 mm on Day 30. The posterior margin increased from 1.2 mm on Day 0 to 2.8 mm on Day 30. The lateral treatment margins increased most over time, with mean right treatment margin increasing from 3.9 mm on Day 0 to 4.7 mm on Day 30. CONCLUSION: Treatment margins appear to be durable in the postimplant period, with a clinically insignificant increase from Day 0 to Day 30.

Brachytherapy↗

PubMed2004

Chronic pelvic pain following prostate brachytherapy: a case report.

PURPOSE: To alert physicians and potential patients that chronic postimplant pelvic pain syndromes can occur, and that dosimetric parameters (i.e., implant technique) may predispose patients to it. METHODS AND MATERIALS: The authors are currently following 3 prostate brachytherapy patients with what appear to be chronic radiation-related pelvic pain, variously exacerbated by urination or perineal pressure. The 3 patients were identified in the course of routine follow-up, and do not represent a concerted attempt to identify such patients from a larger group of patients being followed by the authors. Three control groups of 10 patients each treated with (125)I, (103)Pd, or (103)Pd + external beam radiation and with no reported dysuria at 6 months postimplant were taken from two ongoing prospective trials. The 3 patients reported here were each administered a brief questionnaire regarding the effect of their urinary pain on daily activities. RESULTS: Patients with chronic pain tended to have high central prostatic doses, at least on some planes. Maximal, mean, and median urethral doses were higher for patients with chronic pain, but there was some overlap with control patients. The prostate V100s were similar between patients with chronic pain and controls, but there was a trend toward higher V200s and V300s in pain syndrome patients. CONCLUSION: Recalcitrant brachytherapy-related pelvic pain is an uncommon occurrence that may be partly related to higher central prostatic doses.

Aged↗

PubMed2002

Penile bulb imaging.

PURPOSE: Because of the apparent relationship between potency loss and radiation doses to the erectile bodies, there is increasing rationale for incorporating penile bulb dosimetry into treatment planning and posttreatment evaluation. Because the location and shape of the penile bulb have not been described in detail on various imaging modalities, we herein describe the anatomic boundaries of the penile bulb on computed tomography (CT), magnetic resonance imaging (MR), and transrectal ultrasound (TRUS), before and after brachytherapy. METHODS AND MATERIALS: Nonenhanced axial CT images were taken on a CTi CT Scanner (General Electric Medical Systems, Milwaukee, WI) with the patient in the supine position. Settings were at 300 ma, 140 kvp, 4-s scan time per slice, and collimation of 3 mm with data obtained at 3-mm intervals. Nonenhanced MR images were obtained with a 1.5 Tesla Signa Horizon LX Scanner using fast spin-echo T1-weighted (TR/TE, 466/20) and T2-weighted (TR/TE, 8000/90) images, with a slice thickness of 2 mm and an interslice gap of 0.5 mm. TRUS images were obtained with a Siemens SONOLINE Prima ultrasound machine at 6.0 MHz and a Winston-Barzell stepper unit. RESULTS: The penile bulb is best visualized on T2-weighted MR images in the axial, sagittal, and coronal planes, appearing as an oval-shaped, hyperintense midline structure. On axial CT imaging, the bulb of the penis is typically readily identifiable, bounded by the paired crura laterally, the corpora spongiosum anteriorly, and the levator ani posteriorly. The penile bulb is typically well visualized on transverse TRUS, but usually only faintly seen on sagittal TRUS. The bulb is partially obscured on postimplant CT and MR images, presumably because of implant-related edema. Bulb volumes vary markedly from patient to patient, ranging from 5.6 to 12.4 cc (median: 8.1 cc). CONCLUSION: Closer attention to penile erectile tissue doses should lead to improved external beam radiation and brachytherapy delivery. It will benefit the radiation oncology community to become familiar with these imaging findings, so that penile bulb dosimetry can be incorporated into our daily practice.

Humans↗

PubMedDate not supplied

Extraprostatic seed placement and its effect on seed loss.

PURPOSE: The purpose of this study was to examine the relationship between extraprostatic seed placement and seed loss in a cohort of patients who had underwent both computed tomographic (CT) and magnetic resonance (MR) scans at day 0 and day 30 following brachytherapy. MATERIALS AND METHODS: Twenty-two patients with 1997 AJC clinical stage T1-T2 prostatic carcinoma were implanted with nonstranded I 125. Patients were selected solely by having a prostate volume between 15 and 60 cc and a willingness to return for 30-day follow-up CT and MR scans. The total number of I-125 sources implanted on day 0 ranged from 50 to 104 (median: 70). Preplan treatment planning methods have been previously described in detail: a modified peripheral loading pattern and treatment margins of 5-10 mm were used. Noncontrast postimplantation CT and MR scans were obtained 1-4 hours after implantation on day 0. The total seed count on days 0 and 30 was verified by plain radiograph. Pelvic MR (T1) images were registered with the CT images in the Varian planning system, using bony landmarks. The number of extracapsular seeds in each quadrant of the circumference was then totaled for each patient. A second set of plain radiographs (for seed counting), as well as CT and MR scans, were obtained 30 days after implantation (day 30) and were similarly analyzed. RESULTS: The number of extraprostatic seeds at day 0 ranged from 13 to 35, making up 17%-48% (median: 34%) of the total number implanted. Of the 22 patients, 10 lost one or more seeds between the implantation day and the 1-month follow-up. The mean number of seeds lost was 1.1 (+/- 1.7). There was no apparent relationship between the percent of extraprostatic seeds and the number of seeds lost. There was no apparent relationship between seed loss and number of seeds less than 3 mm or greater than 3 mm from the prostatic capsule. CONCLUSIONS: We have shown here that with CT and MR seed localization, extraprostatic seed placement does not appear to substantially increase the likelihood of seed loss after the procedure.

Brachytherapy↗